HomeAI · summaries
Storia in 3 fonti
Aficamten trial brings positive news for patients living with non-obstructive hypertrophic cardiomyopathy
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, according to results presented today in a Hot Line session at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Aficamten improves health status, exercise capacity in challenging nonobstructive HCM
MUNICH — In patients with symptomatic nonobstructive hypertrophic cardiomyopathy, aficamten led to greater improvements in health status and exercise capacity at 36 weeks compared…
- ·
medpagetoday.com
Nonobstructive Heart Enlargement Responds to Aficamten
Trial results extend range of benefits beyond drug's current indication
